UCB's Keppra Gains Indication As Adjunctive Therapy For Juvenile Myoclonic Epilepsy
This article was originally published in The Pink Sheet Daily
Executive Summary
New indication represents the first U.S. approval for Keppra for the treatment of a generalized seizure type in epilepsy patients.
You may also be interested in...
UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
A key regulatory concern for the biologic is a lack of induction evaluation criteria in one of two pivotal Crohn’s trials, the firm tells “The Pink Sheet” DAILY.
UCB’s Cimzia Could Be Delayed Until 2008 Or Later For Crohn’s
A key regulatory concern for the biologic is a lack of induction evaluation criteria in one of two pivotal Crohn’s trials, the firm tells “The Pink Sheet” DAILY.
UCB Attempts To Protect Keppra Franchise
Company asks FDA to strengthen guidelines associated with generic versions of antiepileptic drugs, as Keppra patent expiration approaches.